Who are SGLT2 inhibitor and DPP-4 inhibitor's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sglt2-inhibitor-and-dpp-4-inhibitor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

SGLT2 inhibitor and DPP-4 inhibitor — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SGLT2 inhibitor and DPP-4 inhibitor (SGLT2 inhibitor and DPP-4 inhibitor) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor and DPP-4 inhibitor combination. Area: Diabetes.

marketed SGLT2 inhibitor and DPP-4 inhibitor combination SGLT2 (sodium-glucose cotransporter 2) and DPP-4 (dipeptidyl peptidase-4) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

SGLT2 inhibitor and DPP-4 inhibitor (SGLT2 inhibitor and DPP-4 inhibitor) — LMC Diabetes & Endocrinology Ltd.. This combination drug lowers blood glucose by blocking kidney glucose reabsorption (SGLT2 inhibitor) and slowing incretin hormone breakdown (DPP-4 inhibitor).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SGLT2 inhibitor and DPP-4 inhibitor TARGET	SGLT2 inhibitor and DPP-4 inhibitor	LMC Diabetes & Endocrinology Ltd.	marketed	SGLT2 inhibitor and DPP-4 inhibitor combination	SGLT2 (sodium-glucose cotransporter 2) and DPP-4 (dipeptidyl peptidase-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor and DPP-4 inhibitor combination class)

LMC Diabetes & Endocrinology Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SGLT2 inhibitor and DPP-4 inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/sglt2-inhibitor-and-dpp-4-inhibitor. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab